Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KAINOS LaboratoriesTSE:4556 39 Return-on-Tangible-Equity is 4.04% as of Mar. 2026, which is 60% below its 10-year median of 10.11. GuruFocus rates TSE:4556 with a GF Score™ of 39/100 and a GF Value™ of 円1,282.66 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 759 Medical Devices & Instruments companies, KAINOS Laboratories ranks better than 55.73% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. KAINOS Laboratories's annualized net income for the quarter that ended in Mar. 2026 was 円286 Mil. KAINOS Laboratories's average shareholder tangible equity for the quarter that ended in Mar. 2026 was 円7,070 Mil. Therefore, KAINOS Laboratories's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 4.04%.
The historical rank and industry rank for KAINOS Laboratories's Return-on-Tangible-Equity or its related term are showing as below:
TSE:4556'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 6.43 Med: 10.11 Max: 10.78
Current: 6.45
During the past 13 years, KAINOS Laboratories's highest Return-on-Tangible-Equity was 10.78%. The lowest was 6.43%. And the median was 10.11%.
TSE:4556's Return-on-Tangible-Equity is ranked better than 55.73% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.04
vs TSE:4556: 6.45
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
KAINOS Laboratories Return-on-Tangible-Equity Related Terms
KAINOS Laboratories Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for KAINOS Laboratories's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4556 vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, KAINOS Laboratories's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KAINOS Laboratories Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, KAINOS Laboratories's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where KAINOS Laboratories's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 4.04% mean?
KAINOS Laboratories (TSE:4556) has a Return-on-Tangible-Equity of 4.04% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on KAINOS Laboratories and its competitors. This is 60% below median its historical median of 10.11. Over the past decade, KAINOS Laboratories' Return-on-Tangible-Equity has ranged from 6.43 to 10.78. According to the industry distribution chart, KAINOS Laboratories ranks #336 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 44.3%.
Is KAINOS Laboratories' Return-on-Tangible-Equity too high?
KAINOS Laboratories' current Return-on-Tangible-Equity of 4.04% is 60% below median its 10-year median of 10.11. Over the past 10 years, this metric has ranged from a low of 6.43 to a high of 10.78. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.04. KAINOS Laboratories' value of 4.04% is 0% at this industry median. Based on the distribution chart, KAINOS Laboratories ranks #336 out of 759 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, KAINOS Laboratories has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does KAINOS Laboratories' Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, KAINOS Laboratories ranks #336 out of 759 companies for Return-on-Tangible-Equity. This puts KAINOS Laboratories in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.04. KAINOS Laboratories' value of 4.04% is 0% at this benchmark. Historically, KAINOS Laboratories' own Return-on-Tangible-Equity has ranged from 6.43 to 10.78 over the past decade. While the company's 10-year median is 10.11 vs. the industry median of 4.04, KAINOS Laboratories has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.04, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. KAINOS Laboratories's current Return-on-Tangible-Equity of 4.04% is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on KAINOS Laboratories and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KAINOS Laboratories's current Return-on-Tangible-Equity is 4.04%, which is 60% below median its own 10-year median of 10.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KAINOS Laboratories stock overvalued right now?
Based on GuruFocus' analysis, KAINOS Laboratories (TSE:4556) is currently considered Significantly Overvalued. The stock's GF Value™ is 円1,282.66, compared to a current price of 円2,268.00 — trading 76.8% above its estimated fair value. The current Return-on-Tangible-Equity is 4.04%, which is 60% below median its 10-year median of 10.11 and 0% at the Medical Devices & Instruments industry median of 4.04. KAINOS Laboratories' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For KAINOS Laboratories (TSE:4556), the current Return-on-Tangible-Equity is 4.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KAINOS Laboratories (TSE:4556) Overvalued in 2026?
Based on GuruFocus' analysis, KAINOS Laboratories stock appears to be overvalued.
The current stock price of 円2,268.00 is trading 76.8% above its estimated GF Value™ of 円1,282.66.
GuruFocus considers KAINOS Laboratories to be Significantly Overvalued.
Key valuation signals for TSE:4556:
Return-on-Tangible-Equity: 4.04% (60% below median its 10-year median of 10.11)
GF Value™: 円1,282.66 vs. price of 円2,268.00 (76.8% above fair value)
Industry Position: 0% at the Medical Devices & Instruments median (#336 of 759)
No single metric tells the full story. See the TSE:4556 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KAINOS Laboratories Inc is focused on the development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products. It also manufactures, sells, and exports/imports physicochemical measuring equipment for medical use.
39GF Score
Get the complete analysis for TSE:4556
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4556 has been successfully added to your 
